Research programme: signal transduction pathway inhibitors - Mercury Therapeutics

Drug Profile

Research programme: signal transduction pathway inhibitors - Mercury Therapeutics

Latest Information Update: 10 Apr 2007

Price : $50

At a glance

  • Originator Mercury Therapeutics
  • Class Small molecules
  • Mechanism of Action Ras signal transduction pathway inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 10 Apr 2007 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 05 Dec 2002 Mercury Therapeutics has acquired exclusive worldwide rights to a drug target from Massachusetts General Hospital
  • 26 Sep 2002 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top